In compliance with Thailand's conditional approval requirements, this prospective, observational study is designed to actively monitor the safety of VacPertagen vaccine. Healthcare professionals (HCPs) prescribing or administering the vaccine are recruited from hospitals and clinics across central, eastern, southern and northern Thailand. Adverse events following immunization (AEFIs) are reported through standardized questionnaires and modified WHO AEFI forms, enabling systematic evaluation of the vaccine's safety profile in a broader and more heterogeneous population than that assessed in pre-licensure trials. Primary objective: To describe the post-licensure safety profile of VacPertagen in Thailand. Secondary objective: To identify any unexpected safety signals following vaccination with VacPertagen.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence and percentage of AEFIs following vaccination with VacPertagen.
Timeframe: From the date of vaccination up to 30 days post-vaccination.
Incidence and percentage of pregnant women vaccinated with VacPertagen who had experienced complications during pregnancy
Timeframe: From administration of VacPertagen during pregnancy until delivery
Incidence and percentage of healthy and not healthy infants born to mothers who received VacPertagen during pregnancy.
Timeframe: From maternal vaccination during pregnancy until birth of the infant.